Among the main reasons for antiviral drug failure are issues related to pharmacokinetic (PK) and pharmacodynamics (PD). To this end, ADMET profiling serves as a critical step in reducing attrition rates during preclinical and clinical stages. ADMET property profiling also provides critical insights into the PK and safety profiles of compounds identified as potentially active against the selected respiratory viral targets. ADMET profiling provides early indications of potential safety issues, including hepatotoxicity, cardiotoxicity and drug-drug interactions. These factors are particularly relevant for antiviral therapies, which are often administered in combination with other treatments. Maintaining sufficient plasma concentrations within the therapeutic window is critical for inhibiting viral replication effectively while minimizing toxicity and preventing resistance. Key PK parameters, such as the volume of distribution (VD) and clearance (Cl) significantly influence a compound's antiviral effectiveness. For all 339,040 compounds in the VS data set (see Table ) forty-one ADMET properties were calculated using ADMET-AI (see Methods Section 2.9 for further details). This detailed profiling is included in the structure file of the VS data set to facilitate a comprehensive evaluation of candidate molecules. The user of the newly assembled and designed libraries is free to use other tools to estimate the ADMET profile of the newly assembled and designed libraries (see Section 3.9). .